Principal Investigator: Mitchell Machtay, MD
Primary Objective:
Test whether the addition of cetuximab to radiation therapy will improve overall survival (OS) in postoperative patients with intermediate risk following surgery
Patient Population:
Pathologically proven diagnosis of squamous cell carcinoma (including variants such as verrucous carcinoma, spindle cell carcinoma, carcinoma NOS, etc.) of the head/neck (oral cavity, oropharynx or larynx); clinical stage T2-T4a, N0-2, M0 or T1, N1-2, M0.
Target Accrual: 700
Current Accrual: 599
Status: Open to Accrual
Date: 11/5/2009
